Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Chalazion 3Uterine Cervical Neoplasms 2Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Sarcoma 1Pilonidal Sinus 1Necrosis 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Mucinoses 1Ganglion Cysts 1Fistula 1Disease Progression 1Connective Tissue Diseases 1Breast Neoplasms 1Advanced Gastric Carcinoma 1

Interventions

Lenalidomide 4Gemcitabine 4Dexamethasone 4Cyclophosphamide 4Bortezomib 4Nivolumab 3Cisplatin 3Carboplatin 3vandetanib 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2pomalidomide 2pembrolizumab 2liposomal doxorubicin 2fludarabine 2durvalumab 2capivasertib 2Radiosurgery 2Paclitaxel 2Doxorubicin 2Bevacizumab 2Anthropogenic Effects 2venetoclax 1umbralisib 1ublituximab 1tremelimumab 1tivozanib 1ricolinostat 1regorafenib 1pazopanib 1niraparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × Conservative Treatment × Clear all
NCT02522585 2016-04-20

p16 and Ki-67 Stainings and Natural Killer (NK) Cells in CIN-II Management

Parc de Salut Mar

Completed
100 enrolled
Gynecologic

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡